Jump to content

CPCCOEt

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by Entranced98 (talk | contribs) at 14:12, 5 November 2022 (+sd). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
CPCCOEt
Identifiers
  • (−)-ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
ChEMBL
Chemical and physical data
FormulaC13H13NO4
Molar mass247.250 g·mol−1
3D model (JSmol)
  • CCOC(=O)C23Oc1ccccc1\C(=N\O)\C2C3
 ☒NcheckY (what is this?)  (verify)

CPCCOEt is a drug used in scientific research, which acts as a non-competitive antagonist at the metabotropic glutamate receptor subtype mGluR1, with high selectivity although only moderate binding affinity.[1][2] It is used mainly in basic research into the function of the mGluR1 receptor,[3][4] including the study of behavioural effects in animals including effects on memory and addiction.[5][6]

See also

[edit]

References

[edit]
  1. ^ Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R (March 1999). "CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding". Molecular Pharmacology. 55 (3): 453–61. PMID 10051528.
  2. ^ Ott D, Floersheim P, Inderbitzin W, Stoehr N, Francotte E, Lecis G, Richert P, Rihs G, Flor PJ, Kuhn R, Gasparini F (November 2000). "Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester". Journal of Medicinal Chemistry. 43 (23): 4428–36. doi:10.1021/jm0009944. PMID 11087567.
  3. ^ Fukunaga I, Yeo CH, Batchelor AM (February 2007). "The mGlu1 antagonist CPCCOEt enhances the climbing fibre response in Purkinje neurones independently of glutamate receptors". Neuropharmacology. 52 (2): 450–8. doi:10.1016/j.neuropharm.2006.08.014. PMID 17045308. S2CID 40361285.
  4. ^ Sugiyama Y, Kawaguchi SY, Hirano T (February 2008). "mGluR1-mediated facilitation of long-term potentiation at inhibitory synapses on a cerebellar Purkinje neuron". The European Journal of Neuroscience. 27 (4): 884–96. doi:10.1111/j.1460-9568.2008.06063.x. PMID 18279362. S2CID 25581416.
  5. ^ Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK (November 2006). "Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties". Drug and Alcohol Dependence. 85 (2): 142–56. doi:10.1016/j.drugalcdep.2006.04.003. PMID 16697125.
  6. ^ Kim J, Lee S, Park H, Song B, Hong I, Geum D, Shin K, Choi S (March 2007). "Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction". Biochemical and Biophysical Research Communications. 355 (1): 188–93. doi:10.1016/j.bbrc.2007.01.125. PMID 17292864.